Neurokinin antagonism and chemotherapy-induced emesis.
Shanahan
F
F
Department of Medicine, Cork Cancer Research Center, National University of Ireland.
O'Sullivan
G C
GC
D000080:Acetals / Q000627:therapeutic use*; D000932:Antiemetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000077608:Aprepitant; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D017829:Granisetron / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009325:Nausea / Q000517:prevention & control; D064729:Neurokinin-1 Receptor Antagonists; D016032:Randomized Controlled Trials as Topic; D013373:Substance P / Q000037:antagonists & inhibitors*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000080:Acetals; D000932:Antiemetics; D000970:Antineoplastic Agents; D000077608:Aprepitant; D002945:Cisplatin; D003907:Dexamethasone; D017829:Granisetron; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D013373:Substance P